Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
BlossomHill Therapeutics›
Website
AddedFeb 15, 2024
UpdatedJun 18, 2026
BlossomHill Therapeutics

BlossomHill Therapeutics

BlossomHill Therapeutics: A biopharma firm innovating in oncology and autoimmune disorder treatments.

HQ
San Diego, CA, US
Founded
2020
Loading
Overview
Compare
Fundraising
Employees
Website

BlossomHill Therapeutics - Website

An index of every page on bhtherapeutics.com, by section.

33 pages across 9 sections · Updated Jul 19, 2026·

Homepage

BlossomHill Therapeutics's front door: current positioning and top-line messaging.

bhtherapeutics.com

Careers

Open roles and how BlossomHill Therapeutics recruits: 4 careers pages straight from the source.

bhtherapeutics.com/careers
  • Four Scientists
  • Flower Hands/careers/attachment/flower_hands
  • Scientist Man Lab

TeamZachary F Zimmerman M D Ph D

Leadership and the people behind BlossomHill Therapeutics, as the company presents them.

  • Zachary F Zimmerman M D Ph D
  • Diane Wang Ph D/team/diane-wang-ph-d
  • Z Jesse Shao Ph D R Ph/team/z-jesse-shao-ph-d-r-ph
  • Eugene Y Rui Ph D/team/eugene-y-rui-ph-d
  • Antonio Garrido Montalban Phd
  • Geoff Oxnard M D/team/geoff-oxnard-m-d

Contact

Sales, support, and partnership channels for reaching BlossomHill Therapeutics directly.

bhtherapeutics.com/contact
  • Map V2/contact/attachment/map-v2
  • Contact Ladybug Flower
  • Map/contact/attachment/map
  • Flowerfield Contact

About

Company story, mission, and background as BlossomHill Therapeutics tells it.

bhtherapeutics.com/about
  • Dsc 2176 Crop2 About
  • About Torrey Pines Flowers
  • Jean Founder 2/about/attachment/jean_founder-2
  • Jean Founder/about/attachment/jean_founder
  • About Patient/about/attachment/about_patient

BlogNews

Product updates, deep-dives, and company thinking: BlossomHill Therapeutics's 3-post archive.

bhtherapeutics.com/news
  • News Flowers/news/attachment/news_flowers
  • Flower Phone Hands

PressLife Science Vets Leading Blossomhills Lung Cancer Treatment Pipeline

Official announcements and statements: 6 pages in BlossomHill Therapeutics's own words.

  • Life Science Vets Leading Blossomhills Lung Cancer Treatment Pipeline
  • Blossomhill Advancing Egfr Clk Inhibitors with Series B Extension
  • Blossomhill Gets Another 84M for Macrocyclic Approach to Egfr
  • Blossomhill Raises 100M in Bid to Repeat Founders Cancer Success at Turning Point
  • This Chemists Last Startup Sold for 4 Billion Now Investors Have Poured 173 Million into Her Next Act
  • With Seeds from Turning Point a New Biotech Blooms with 100M to Take on Small Molecules

ComparisonAacr Discovery of Bh 30236 a Novel Macrocyclic Clk Inhibitor Targeting Alternative Splicing in Cancers

Comparison page published by BlossomHill Therapeutics.

bhtherapeutics.com/aacr_discovery-of-bh-30236-a-novel-macrocyclic-clk-inhibitor-targeting-alternative-splicing-in-cancers

TermsTerms of Service

The legal agreement governing use of BlossomHill Therapeutics's products and services.

bhtherapeutics.com/terms-of-service